SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is generating significant community discussion driven by its integration with World Liberty Financial's $USD1 for payroll and card services, alongside anticipation for its Super App and updated tokenomics. Investors are highlighting its real-world utility in on-chain payroll and payments, emphasizing its ISO 20022 and MiCA compliance, and low dilution as key factors attracting bullish sentiment.

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is trending as a highly speculative meme coin, generating significant community buzz, often alongside its related token $BALLSACK. Discussion ranges from humorous "all-in" declarations to widespread criticism regarding the perceived "useless" utility and the overall speculative nature of such projects in the crypto market.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE is generating significant buzz within the crypto community, largely due to its recent listing on MEXC Meme+ and an energetic social presence. Discussions center on its 'AI dog' branding, speculated connection to Grok, and a highly engaged community that views it as a potential standout in the meme coin landscape.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending due to its recently strengthened balance sheet from a completed pension reversion, which is fueling investor excitement around its strategic pivot into pharmaceutical API manufacturing and advanced battery materials. The community actively anticipates significant government contracts for domestic pharma supply chains and a resurgence in film sales, leading many to expect a substantial revaluation and a 'Kodak moment' surge.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is actively trending as its dedicated community champions the crypto's deep ties to cannabis culture, positioning it as a 'plant-paced' project on the Solana blockchain. Enthusiasts consistently rally around the mantra of holding 'Bongterm' and proclaiming it to be 'like Bitcoin but way higher,' while also engaging in discussions about the broader utility and cultural significance of hemp within the ecosystem. This sustained community-driven narrative is the primary catalyst for its current momentum.

ChargePoint Holdings, Inc. operates as an electric vehicle charging network provider. It designs, develops and markets networked electric vehicle charging system infrastructure and its Cloud Services enable consumers the ability to locate, reserve, authenticate and transact electric vehicle charging sessions. The firm provides an open platform providing real-time information about charging sessions and control, support and management of the networked charging systems. This network provides multiple web-based portals for charging system owners, fleet managers, drivers and utilities. The company was founded in 2007 and is headquartered in Campbell, CA.

ChargePoint Holdings Inc - Ordinary Shares - Class A

ChargePoint Holdings Inc

ChargePoint is trending as its recent financial results, showing revenue growth and margin improvement alongside debt reduction, have ignited debate among investors. While some view these improvements and strategic partnerships as signs of a potential turnaround for the EV charging infrastructure leader, many in the community remain cautious, citing concerns over past performance, dilution, and the broader profitability challenges within the evolving EV sector. The mixed sentiment reflects ongoing discussions about the company's ability to capitalize on long-term EV adoption despite current hurdles.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is heavily discussed following its recent shareholder meeting and a significant $200 million investment in Mr. Beast Industries, drawing strong reactions from the community. Many investors are expressing deep concern over the strategic direction, perceived dilution, and no-shows from anticipated high-profile speakers, causing frustration with management's capital allocation. However, a segment of the community views the Mr. Beast partnership as a potential "moonshot" for long-term growth and broader exposure, diversifying its Ethereum-focused treasury.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF ($SMH) is experiencing strong upward momentum, driven by solid earnings from major chipmakers like TSMC and optimistic forecasts for artificial intelligence demand. While this has propelled the sector to new highs, a notable portion of the community expresses caution, fearing the current valuation may be overextended and potentially signaling a market 'bubble' ahead of upcoming earnings reports for other components.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy Inc

T1 Energy is trending as it fortifies its standing as a domestic solar manufacturer, securing crucial FEOC compliance and a significant supply deal for its Texas facilities. The community is actively discussing the company's potential undervaluation and its strategic role in addressing the escalating energy demands of AI data centers. Investors view recent capital raises as foundational for its aggressive growth trajectory and market share expansion.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is a major focus as geopolitical tensions, particularly regarding Russian and Venezuelan oil supply and new US sanctions, intensify debates around energy market stability. Amid fluctuating crude prices, community sentiment points to strong underlying demand drivers like AI-driven electricity needs and sector rotation, positioning XLE for a potential long-term breakout despite some 'oversupplied' narratives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?

Amicus stock soars 135.8% in six months as demand for marketed products grows. The company is set to be acquired by BioMarin for $4.8 billion.

<ul class="summary-bullets"><li>FDA is slated to decide on Disc Medicine's Bitopertin by February.&nbsp;</li><li>Approval for Lilly’s obesity pill is expected by April 10.</li><li>The FDA has also stalled the review of Sanofi’s Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.</li></ul>Shares of Dis Medicine (IRON) fell 7% on Thursday after the U.S. Food and Drug Administration (FDA) reportedly delayed review of its drug Bitopertin despite choosing it for fast track review under a new voucher program.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-delays-two-drug-reviews-new-voucher-program-after-safety-efficacy-2026-01-15/">reported</a> on Thursday, citing internal documents, that the FDA delayed the review of the company’s experimental drug for treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns. EPP is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The reviewers pushed the drug’s potential approval by two weeks to Feb. 10 as they examine whether it has abuse risks. The agency also has concerns if pain-free time in the sun is a statistically solid measure of efficacy or if other data can justify approval, the report said.Disk Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">Sanofi Faces Longer Delay</h2>The FDA has also stalled the review of Sanofi’s (SNY) Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.The agency is considering the death of a patient while taking the drug and also evaluating two reports related to seizure and blood clotting. The agency was initially slated to decide on the application by Nov. 21.<h2 class="st-heading-2">Lilly’s Weight-Loss Drug Approval Now Slated For Q2</h2>Other drugs to face delays beyond the original target date include Boehringer Ingelheim's zongertinib for lung cancer and Eli Lilly’s (LLY) weight-loss pill. While zongertinib approval is now expected in mid-February, approval for Lilly’s obesity pill is expected by April 10, later than its initial first quarter (Q1) estimate, Reuters said.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 4% lower at the time of writing while <a href="https://stocktwits.com/symbol/SNY">SNY shares</a> fell 1%.According to Reuters, at least seven drugs selected for priority review have started the approval process. While most of the reviews for the drugs selected for the program are slated to start this year, others are scheduled for 2027 and 2028.Only one antibiotic drug has been approved under the program as of date called Augmentin XR.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON and SNY stocks trended in the ‘Neutral’ territory at the time of writing. Retail sentiment around LLY, however, rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours.A Stocktwits user dismissed the delay report as a “short term hiccup.”<stembedurl>https://www.stocktwits.com/wwmeinc/message/641906137</stembedurl>Another opined that the selloff in IRON shares is a buying opportunity.<stembedurl>https://www.stocktwits.com/StockBraker/message/641896960</stembedurl><a href="https://stocktwits.com/symbol/IRON">DISC stock</a> has gained 18% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-contemplating-deal-with-chinese-rival-byd-as-it-seeks-to-scale-hybrids-report/cmU1pwgR4JJ">Ford Contemplating Deal With Chinese Rival BYD As It Seeks To Scale Hybrids: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.

Equity

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.


Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.

<ul class="summary-bullets"><li>Ocular Therapeutix had reportedly rejected Sanofi’s initial takeover bid in September.</li><li>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology.</li><li>Sanofi recently acquired Dynavax to boost its vaccine portfolio.</li></ul>Ocular Therapeutix (OCUL) was back on retail’s radar, with the stock surging 13% in premarket trading on Thursday, after reports emerged that French pharmaceutical giant Sanofi (SNY) is preparing an offer to acquire the American biopharmaceutical firm.According to French publication La Lettre, the renewed interest comes after Ocular Therapeutix rejected Sanofi’s initial takeover bid in September, when the group offered $16 per share, a substantial premium to Ocular’s then-trading price of about $10.50.<a href="https://stocktwits.com/symbol/OCUL">OCUL shares</a> have been on a downtrend lately, declining in 11 of the last 13 sessions. <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> was down 0.4% in pre-open trade.<h2 class="st-heading-2">Acquisition Rationale</h2>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology, particularly in age-related macular degeneration, which affects the central part of the retina.At the same time, it could support Sanofi’s push into combination therapies, with Ocular’s treatments, such as Dextenza for ocular inflammation, potentially pairing well with existing drugs like Dupixent, given studies suggesting links between chronic skin conditions and eye disorders such as cataracts.<h2 class="st-heading-2">Sanofi’s Acquisition Spree</h2>Sanofi has been ramping up its strategy to add to its portfolio through key acquisitions over the last few months. In late December, Sanofi signed an agreement to acquire vaccine maker Dynavax Technologies Corp (DVAX) in a <a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">$2.2 billion deal</a> aimed at strengthening its adult immunization portfolio. The transaction will strengthen Sanofi’s global vaccines business by bringing in Dynavax’s approved adult hepatitis B vaccine, HEPLISAV-B, along with a differentiated shingles vaccine.In June, Sanofi agreed to <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">acquire Blueprint</a> Medicines for about $9.1 billion to deepen its presence in the cure for rare immunological diseases. The acquisition added Ayvakit/Ayvakyit, the only approved treatment for systemic mastocytosis, along with pipeline assets including Elenestinib and BLU-808 to Sanofi’s portfolio.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for OCUL on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/OCUL_jpg_9ede93e8cf.webp" alt="OCUL.jpg" width="928" height="100"><figcaption>OCUL's Sentiment Meter and Message Volumes at Premarket on Jan. 15, 2026 | Source: Stocktwits</figcaption></figure>One user sees upside in OCUL stock due to the offer.<stembedurl>https://stocktwits.com/scholar9/message/641880419</stembedurl>OCUL shares have gained around 34% over the past year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/nasdaq-sp500-futures-pause-nvda-tsm-msft-cvx-stocks-to-watch/cmU1L2fR47N">Nasdaq, S&amp;P 500 Futures Pause Ahead Of Major Bank Earnings, Jobless Claims: Why NVDA, TSM, CVX, MSFT, AMZN Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OCUL Stock Jump 13% In Pre-Market Today?

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing

Sanofi (NASDAQ:SNY) Given Average Rating of "Moderate Buy" by Brokerages

Sanofi (NASDAQ:SNY - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Six analysts have...

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes

SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.

<ul class="summary-bullets"><li>JNJ agreed to drug discounts and tariff exemptions under a White House deal.</li><li>The agreement builds on its existing $55 billion U.S. manufacturing and R&amp;D plan.</li><li>New facilities add to projects already underway in North Carolina and Pennsylvania.</li></ul>Johnson &amp; Johnson (JNJ) said on Thursday it has reached a voluntary agreement with the U.S. government to expand access to medicines, lower drug costs for American patients, and secure exemptions from U.S. tariffs on its pharmaceutical products, while advancing its domestic manufacturing plans.<h2 class="st-heading-2">Drug Pricing And Tariff Exemptions</h2>As part of the deal, JNJ will allow Americans to buy medicines at significantly discounted rates through TrumpRx.gov, a government-backed direct-to-patient platform. The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.The deal grants JNJ’s pharmaceutical products exemptions from U.S. tariffs and aligns with the administration’s “most-favored-nation” pricing framework.“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” CEO Joaquin Duato said in a statement.&nbsp;<h2 class="st-heading-2">US Manufacturing Commitments</h2>JNJ said the agreement builds on its previously announced $55 billion U.S. investment plan through early 2029, which focuses on expanding domestic manufacturing, research and development, and technology.&nbsp;As part of the plan, the company announced two additional U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product manufacturing facility in North Carolina. Construction is already underway at the company’s $2 billion biologics facility in Wilson, North Carolina, a project expected to support around 5,000 manufacturing and construction jobs.&nbsp;Separately, JNJ has committed $2 billion over the next 10 years to a biopharmaceutical site in Holly Springs, North Carolina, which is expected to create about 120 jobs. The company said it expects to announce further U.S. investments later this year.<h2 class="st-heading-2">White House Drug Deals Expand</h2>The announcement follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">similar agreements struck last month</a> between the White House and other major drugmakers, including Amgen, Bristol Myers Squibb, Pfizer, Gilead Sciences, GSK, Merck, Novartis, Roche and Sanofi.The deals require steep discounts through TrumpRx, most-favored-nation pricing for Medicaid, expanded U.S. manufacturing, and restrictions on stockpiling drugs to avoid tariffs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/jnj_ss_png_1d85f7828a.webp" alt="jnj ss.png" width="967" height="142"><figcaption>JNJ sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/JNJ">JNJ’s stock</a> has risen 49% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs 

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up

DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.

Sanofi (NASDAQ:SNY) Lowered to Equal Weight Rating by Barclays

Barclays downgraded Sanofi from an "overweight" rating to an "equal weight" rating in a research report on Tuesday...

Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?

Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.84	--	--	N/A
Q3 '25	$1.58	$1.69	7.23%	BEAT
Q2 '25	$0.96	$0.91	-5.11%	MISSED
Q1 '25	$0.93	$0.78	-15.53%	MISSED
Q4 '24	$0.70	$0.68	-2.50%	MISSED

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest SNY News

SNYSanofi-Aventis